EXACT SCIENCES CORP: New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making

- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON

Related Keywords

Canada ,United States ,San Antonio ,Texas ,America ,Kevin Kalinsky ,Rick Baehner ,Federico Maiardi ,Stephanie Spanos ,Megan Jones ,Sciences Corp ,Sciences On Facebook ,National Cancer Institute ,Precision Oncology At Exact Sciences ,Sciences On Twitter Exactsciences ,Nasdaq ,Exchange Commission ,Prnewswire Exact Sciences Corp ,Genomic Health Inc ,Cancer Research Network ,Sciences Corporation ,Antonio Breast Cancer Symposium ,Recurrence Score ,Research Network ,Precision Oncology ,New England Journal ,Princess Margaret Trial ,Exact Sciences ,Poster Sessions ,Spotlight Poster Discussions ,North East England ,Using Oncotype ,Cancer Tissue ,Genomic Health ,Risk Factors ,Annual Report ,Quarterly Reports ,Latin America ,Oral Presentation ,San Antonio Breast Cancer Symposium ,Breast Can Res Treat ,Ann Surg ,Exact ,Ciences ,Orp ,Data ,Resented ,Abcs ,021 ,Trengthen ,Value ,Oncotype ,Breast ,Recurrence ,Core ,Pest ,Enform ,Linical ,Decision ,Baking ,